Home LiteratureArticle Details
PMID: 12490596 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves.

The Journal of pharmacology and experimental therapeutics ·Vol. 304 ·No. 1 ·2003-01-00 ·Pages 229-37

Kurrasch-Orbaugh DM, Watts VJ, Barker EL, Nichols DE

Abstract

NIH3T3 cells stably expressing the rat 5-hydroxytryptamine 2A (5-HT 2A) receptor (5500 fmol/mg) were used to explore further the capacity of structurally distinct ligands to elicit differential signaling through the phospholipase C (PLC) or phospholipase A 2 (PLA 2) signal transduction pathways. Initial experiments were designed to verify that 5-HT 2A receptor-mediated PLA 2 activation in NIH3T3 cells is independent from, and not a subsequent result of, 5-HT 2A receptor-mediated PLC activation. In addition, we also explored the extent of receptor reserve for the endogenous ligand, 5-HT, for both PLC and PLA 2 activation. Finally, we employed structurally diverse ligands from the tryptamine, phenethylamine, and ergoline families of 5-HT 2A receptor agonists to test the hypothesis of agonist-directed trafficking of 5-HT 2A receptor-mediated PLC and PLA 2 activation. To measure agonist-induced pathway activation, we determined the potency and intrinsic activity of each compound to activate either the PLA 2 pathway or the PLC pathway. The results showed that a larger receptor reserve exists for 5-HT-induced PLA 2 activation than for 5-HT-induced PLC activation. Furthermore, the data support the hypothesis of agonist-directed trafficking in NIH3T3-5HT 2A cells because structurally distinct ligands were able to induce preferential activation of the PLC or PLA 2 signaling pathway. From these data we conclude that structurally distinct ligands can differentially regulate 5-HT 2A receptor signal transduction.

MeSH Terms
3T3 Cells Adrenergic alpha-Antagonists/pharmacology Animals Arachidonic Acid/metabolism Enzyme Activation/physiology Enzyme Inhibitors/pharmacology Ergolines/pharmacology Hydrolysis Ligands Mice Phenethylamines/pharmacology Phenoxybenzamine/pharmacology Phosphatidylinositols/metabolism Phospholipases A/antagonists & inhibitors,metabolism Phospholipases A2 Radioligand Assay Rats Receptor, Serotonin, 5-HT2A Receptors, Serotonin/metabolism Serotonin Antagonists/pharmacology Serotonin Receptor Agonists/pharmacology Signal Transduction/drug effects,physiology Tryptamines/pharmacology Type C Phospholipases/antagonists & inhibitors,metabolism
Chemicals
Adrenergic alpha-Antagonists Enzyme Inhibitors Ergolines Ligands Phenethylamines Phosphatidylinositols Receptor, Serotonin, 5-HT2A Receptors, Serotonin Serotonin Antagonists Serotonin Receptor Agonists Tryptamines Phenoxybenzamine Arachidonic Acid Phospholipases A Phospholipases A2 Type C Phospholipases
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Kurrasch-Orbaugh Deborah M
Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmacological Sciences, Purdue University, West Lafayette, Indiana 47907, USA.
Watts Val J
Barker Eric L
Nichols David E
Article Info
Journal
The Journal of pharmacology and experimental therapeutics
Abbr.
J Pharmacol Exp Ther
ISSN
0022-3565
Published
2003-01-00
Pages
229-37
Language
English
Region
United States
NLM ID
0376362
Subset
IM
Grants
NIDA NIH HHS · DA02189 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com